Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Karl Jochen Krenosz"'
Autor:
Heinz Ludwig, Bela Hausmann, Martin Schreder, Wolfram Pönisch, Niklas Zojer, Stefan Knop, Eberhard Gunsilius, Alexander Egle, Andreas Petzer, Hermann Einsele, Roman Hajek, Katja Weisel, Karl Jochen Krenosz, Alois Lang, Daniel Lechner, Richard Greil, David Berry
Publikováno v:
eJHaem, Vol 2, Iss 1, Pp 99-103 (2021)
Abstract Alterations in the human microbiome have been linked to several malignant diseases. Here, we investigated the oral microbiome of 79 patients with relapsed/refractory multiple myeloma (MM) treated with ixazomib‐thalidomide‐dexamethasone.
Externí odkaz:
https://doaj.org/article/9b3e8f9b4f614f6ba3c8e6cd95321a0f
Autor:
Katja Weisel, David Berry, Eberhard Gunsilius, Bela Hausmann, Niklas Zojer, Andreas L. Petzer, Martin Schreder, Daniel Lechner, Richard Greil, Stefan Knop, Karl Jochen Krenosz, Hermann Einsele, Heinz Ludwig, Alois Lang, Roman Hájek, Wolfram Pönisch, Alexander Egle
Publikováno v:
eJHaem. 2:99-103
Alterations in the human microbiome have been linked to several malignant diseases. Here, we investigated the oral microbiome of 79 patients with relapsed/refractory multiple myeloma (MM) treated with ixazomib-thalidomide-dexamethasone. Increased alp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa70ce9f0d4f2306fa1c05eacf7bb3e8
https://doi.org/10.1002/jha2.130
https://doi.org/10.1002/jha2.130
Autor:
Stefan Knop, Richard Greil, Karl Jochen Krenosz, Wolfram Poenisch, Hermann Einsele, Katja Weisel, Thomas Melchardt, Andreas L. Petzer, Martin Schreder, Roman Hájek, Dietger Niederwieser, Niklas Zojer, Wolfgang Willenbacher, Daniel Lechner, Heinz Ludwig, Eberhard Gunsilius, Alexander Egle
Publikováno v:
British Journal of Cancer
Background Ixazomib-revlimid-dexamethason showed significant activity in relapsed/refractory multiple myeloma (RRMM). Here, we evaluate ixazomib in combination with thalidomide and dexamethasone for induction treatment followed by ixazomib maintenanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dadb0cb1b333fdfbce192051ed5f7c4
https://doi.org/10.1038/s41416-019-0581-8
https://doi.org/10.1038/s41416-019-0581-8
Autor:
Sandra Nolte, Roman Hájek, Stefan Knop, Thomas Melchardt, Martin Schreder, Andreas L. Petzer, Alexander Egle, Angela Meckl, Tomas Jelinek, Daniel Lechner, Heinz Ludwig, Axel Hinke, Hermann Einsele, Eberhard Gunsilius, Karl Jochen Krenosz, Richard Greil, Katja Weisel, Wolfram Pönisch, Dietger Niederwieser, Holger Rumpold, Ludek Pour, Niklas Zojer, Wolfgang Willenbacher
Publikováno v:
Leukemialymphoma. 61(2)
This trial evaluated quality of life (QoL) using the EORTC QLQ-C30 and the EORTC QLQ-MY20 instruments in 90 patients with relapsed/refractory multiple myeloma during induction and maintenance therapy with eight cycles of ixazomib-thalidomide-dexameth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f50f7d7b8fe2967d28cd50f2bb750988
https://pubmed.ncbi.nlm.nih.gov/31556753
https://pubmed.ncbi.nlm.nih.gov/31556753
Autor:
Wolfram Pönisch, Niklas Zojer, Richard Greil, Eberhard Gunsilius, Karl Jochen Krenosz, Daniel Lechner, Martin Schreder, Heinz Ludwig, Hermann Einsele, Roman Hájek, Stefan Knop, Katja Weisel, Andreas L. Petzer
Publikováno v:
Blood. 132:3275-3275
Introduction Ixazomib is an effective PI that combines the advantage of oral administration with a favorable toxicity profile. Recent results showed significant activity, both in newly diagnosed, and in pretreated patients (pts). Ixazomib in combinat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f287b9e4da398273af69c9e4910fb9d6
https://doi.org/10.1182/blood-2018-99-118061
https://doi.org/10.1182/blood-2018-99-118061